Zevra Therapeutics

ZVRA

Market cap $503M

Zevra Therapeutics reported Q3 FY25 revenues of $26.1M, up 605% YoY, driven by MIPLYFFA, and is nearing profitability. ZVRA's valuation appears deeply discounted, with significant upside from EU expansion, pipeline assets Celiprolol and KP-1077, and a strong $200M cash position. FY26 is projected as the first year of true profitability, with analyst EPS estimates between $0.29 and $1.07 and revenue growth driven by MIPLYFFA.

CELEBRATION, Fla., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted options to purchase an aggregate of 53,000 shares of the Company's common stock (the “Inducement Awards”) to three new employees pursuant to the Company's 2023 Employment Inducement Award Plan (as amended and/or restated, the “Inducement Award Plan”). Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee's start date, and the remainder vesting in three equal annual installments thereafter (subject to each such employee's continued employment on each vesting date).

CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the appointment of Alicia Secor to the Company's Board of Directors (Board). The Company also announced the retirement of director Wendy Dixon, PhD, effective today.

CELEBRATION, Fla., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced today that its Chief Financial Officer and Treasurer, R. LaDuane Clifton, will be stepping down from his position with the Company, effective December 31, 2025, in order to pursue other professional opportunities.

Zevra Therapeutics, Inc. ( ZVRA ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Nichol Ochsner - Vice President of Investor Relations & Corporate Communications Neil McFarlane - President, CEO & Director Joshua Schafer - Chief Commercial Officer R. Clifton - CFO & Treasurer Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Samantha Corwin - William Blair & Company L.L.C.

Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.69 per share a year ago.

2025 EPS of $(0.01) Q3 2025 net revenue of $26.1 million , driven by MIPLYFFA ® net revenue of $22.4 million Company to host conference call and webcast TODAY, November 5, 2025 , at 4:30 p.m. ET CELEBRATION, Fla.

CELEBRATION, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will participate in a fireside discussion at Guggenheim's 2nd Annual Healthcare Innovation Conference in Boston, MA on Wednesday, November 12, 2025, at 11:30 a.m. ET.

- Company will host conference call at 4:30 p.m. ET on Wednesday, November 5, 2025 - Company will host conference call at 4:30 p.m. ET on Wednesday, November 5, 2025

Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.